Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 174,246	$ 165,016	$ 397,132	$ 428,561
Employee and Director Stock Option Grants [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	174,246	168,068	397,470	426,157
Employee and Director Stock Option Grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	22,281	25,749	46,651	109,402
Employee and Director Stock Option Grants [Member] \| General and administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	151,965	142,319	350,819	316,755
Non Employee Consultant Stock Option Grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 0	$ (3,052)	$ (338)	$ 2,404